Pasritamig (JNJ-78278343, KLCB-245) is a Human kallikrein 2 (KLK2) and CD3 receptor complex binder. Pasritamig directs T-cell cytotoxicity to KLK2-expressing tumor cells, induces T-cell-mediated lysis of KLK2-expressing prostate cancer cells. Pasritamig exhibits antitumor activity against metastatic castration-resistant prostate cancer. Pasritamig demonstrates a safety profile with very low rates of cytokine release syndrome, and can be safely administered in an outpatient setting. Pasritamig can be used for the research of metastatic castration-resistant prostate cancer[1].
Molecular Weight:
(124.81 kDa)
Purity:
99.42
CAS Number:
[2921676-04-0]
Target:
CD3
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted
